Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials
There is currently no effective pharmacological therapy to improve the cognitive dysfunction of individuals with Down syndrome (DS). Due to the overexpression of several chromosome 21 genes, cellular and systemic oxidative stress (OS) is one of the most important neuropathological processes that con...
Wedi'i Gadw mewn:
Prif Awduron: | , |
---|---|
Fformat: | Llyfr |
Cyhoeddwyd: |
MDPI AG,
2020-08-01T00:00:00Z.
|
Pynciau: | |
Mynediad Ar-lein: | Connect to this object online. |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
Rhif Galw: |
A1234.567 |
---|---|
Copi 1 | Ar gael |